HHSN261200433001C/PHS HHS/United States[Grant Number] - Search Results

Year	Number of Results
2005	1
2006	1
2008	1
2009	2
2010	1
2012	1
2013	3
2021	0

1

Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis.

Lubet RA, Szabo E, Iwata KK, Gill SC, Tucker C, Bode A, Steele VE, Juliana MM, Nicastro HL, Grubbs CJ. Lubet RA, et al. Cancer Prev Res (Phila). 2013 May;6(5):448-54. doi: 10.1158/1940-6207.CAPR-12-0322. Epub 2013 Mar 26. Cancer Prev Res (Phila). 2013. PMID: 23531447 Free PMC article.

2

Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.

Lubet RA, Clapper ML, McCormick DL, Pereira MA, Chang WC, Steele VE, Fischer SM, Juliana MM, Grubbs CJ. Lubet RA, et al. Oncol Rep. 2012 May;27(5):1400-6. doi: 10.3892/or.2012.1673. Epub 2012 Feb 3. Oncol Rep. 2012. PMID: 22307264

3

Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene).

Vedell PT, Lu Y, Grubbs CJ, Yin Y, Jiang H, Bland KI, Muccio DD, Cvetkovic D, You M, Lubet R. Vedell PT, et al. Mol Pharmacol. 2013 Mar;83(3):698-708. doi: 10.1124/mol.112.082404. Epub 2013 Jan 4. Mol Pharmacol. 2013. PMID: 23292798 Free PMC article.

4

Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy.

Lubet RA, Steele VE, Juliana MM, Grubbs CJ. Lubet RA, et al. J Urol. 2010 Apr;183(4):1598-603. doi: 10.1016/j.juro.2009.12.001. Epub 2010 Feb 20. J Urol. 2010. PMID: 20172542

5

Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.

Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ. Lubet RA, et al. Int J Cancer. 2008 Nov 15;123(10):2254-9. doi: 10.1002/ijc.23765. Int J Cancer. 2008. PMID: 18712722 Free article.

6

Induced expression of drug metabolizing enzymes by preventive agents: role of the antioxidant response element.

Lubet RA, Yao R, Grubbs CJ, You M, Wang Y. Lubet RA, et al. Chem Biol Interact. 2009 Nov 10;182(1):22-8. doi: 10.1016/j.cbi.2009.08.011. Epub 2009 Aug 18. Chem Biol Interact. 2009. PMID: 19695238 Free PMC article.

7

Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.

Lu Y, You M, Ghazoui Z, Liu P, Vedell PT, Wen W, Bode AM, Grubbs CJ, Lubet RA. Lu Y, et al. Cancer Prev Res (Phila). 2013 Nov;6(11):1151-61. doi: 10.1158/1940-6207.CAPR-13-0126. Epub 2013 Sep 25. Cancer Prev Res (Phila). 2013. PMID: 24067424 Free PMC article.

8

Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers.

Grubbs CJ, Lubet RA, Atigadda VR, Christov K, Deshpande AM, Tirmal V, Xia G, Bland KI, Eto I, Brouillette WJ, Muccio DD. Grubbs CJ, et al. Carcinogenesis. 2006 Jun;27(6):1232-9. doi: 10.1093/carcin/bgi308. Epub 2005 Dec 12. Carcinogenesis. 2006. PMID: 16344269

9

Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.

Lubet RA, Boring D, Steele VE, Ruppert JM, Juliana MM, Grubbs CJ. Lubet RA, et al. Cancer Prev Res (Phila). 2009 Feb;2(2):161-7. doi: 10.1158/1940-6207.CAPR-08-0134. Cancer Prev Res (Phila). 2009. PMID: 19196723 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results